10-Q 1 bcrx-20220630.htm 10-Q bcrx-20220630
0000882796--12-312022Q2falseP10Y00008827962022-01-012022-06-3000008827962022-07-29xbrli:shares00008827962022-06-30iso4217:USD00008827962021-12-31iso4217:USDxbrli:shares0000882796us-gaap:ProductMember2022-04-012022-06-300000882796us-gaap:ProductMember2021-04-012021-06-300000882796us-gaap:ProductMember2022-01-012022-06-300000882796us-gaap:ProductMember2021-01-012021-06-300000882796us-gaap:RoyaltyMember2022-04-012022-06-300000882796us-gaap:RoyaltyMember2021-04-012021-06-300000882796us-gaap:RoyaltyMember2022-01-012022-06-300000882796us-gaap:RoyaltyMember2021-01-012021-06-300000882796bcrx:MilestoneRevenueMember2022-04-012022-06-300000882796bcrx:MilestoneRevenueMember2021-04-012021-06-300000882796bcrx:MilestoneRevenueMember2022-01-012022-06-300000882796bcrx:MilestoneRevenueMember2021-01-012021-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMember2022-04-012022-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMember2021-04-012021-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMember2022-01-012022-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMember2021-01-012021-06-3000008827962022-04-012022-06-3000008827962021-04-012021-06-3000008827962021-01-012021-06-3000008827962020-12-3100008827962021-06-300000882796us-gaap:CommonStockMember2021-12-310000882796us-gaap:AdditionalPaidInCapitalMember2021-12-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000882796us-gaap:RetainedEarningsMember2021-12-310000882796us-gaap:RetainedEarningsMember2022-01-012022-03-3100008827962022-01-012022-03-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000882796us-gaap:CommonStockMember2022-01-012022-03-310000882796us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000882796us-gaap:CommonStockMember2022-03-310000882796us-gaap:AdditionalPaidInCapitalMember2022-03-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000882796us-gaap:RetainedEarningsMember2022-03-3100008827962022-03-310000882796us-gaap:RetainedEarningsMember2022-04-012022-06-300000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000882796us-gaap:CommonStockMember2022-04-012022-06-300000882796us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000882796us-gaap:CommonStockMember2022-06-300000882796us-gaap:AdditionalPaidInCapitalMember2022-06-300000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000882796us-gaap:RetainedEarningsMember2022-06-300000882796us-gaap:CommonStockMember2020-12-310000882796us-gaap:AdditionalPaidInCapitalMember2020-12-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000882796us-gaap:RetainedEarningsMember2020-12-310000882796us-gaap:RetainedEarningsMember2021-01-012021-03-3100008827962021-01-012021-03-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000882796us-gaap:CommonStockMember2021-01-012021-03-310000882796us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000882796us-gaap:CommonStockMember2021-03-310000882796us-gaap:AdditionalPaidInCapitalMember2021-03-310000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000882796us-gaap:RetainedEarningsMember2021-03-3100008827962021-03-310000882796us-gaap:RetainedEarningsMember2021-04-012021-06-300000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000882796us-gaap:CommonStockMember2021-04-012021-06-300000882796us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000882796us-gaap:CommonStockMember2021-06-300000882796us-gaap:AdditionalPaidInCapitalMember2021-06-300000882796us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000882796us-gaap:RetainedEarningsMember2021-06-300000882796bcrx:RoyaltyReceivableMember2022-06-300000882796bcrx:RoyaltyReceivableMember2021-12-310000882796bcrx:CollateralForCreditMember2022-06-300000882796bcrx:CollateralForCreditMember2021-12-310000882796srt:MaximumMember2022-01-012022-06-300000882796us-gaap:ComputerEquipmentMember2022-01-012022-06-300000882796bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember2022-01-012022-06-300000882796us-gaap:FurnitureAndFixturesMember2022-01-012022-06-300000882796bcrx:ORLADEYOMemberus-gaap:ProductMember2022-04-012022-06-300000882796bcrx:ORLADEYOMemberus-gaap:ProductMember2021-04-012021-06-300000882796bcrx:ORLADEYOMemberus-gaap:ProductMember2022-01-012022-06-300000882796bcrx:ORLADEYOMemberus-gaap:ProductMember2021-01-012021-06-300000882796bcrx:RAPIVABMemberus-gaap:ProductMember2022-04-012022-06-300000882796bcrx:RAPIVABMemberus-gaap:ProductMember2021-04-012021-06-300000882796bcrx:RAPIVABMemberus-gaap:ProductMember2022-01-012022-06-300000882796bcrx:RAPIVABMemberus-gaap:ProductMember2021-01-012021-06-300000882796bcrx:PERAMIVIRMemberus-gaap:ProductMember2022-04-012022-06-300000882796bcrx:PERAMIVIRMemberus-gaap:ProductMember2021-04-012021-06-300000882796bcrx:PERAMIVIRMemberus-gaap:ProductMember2022-01-012022-06-300000882796bcrx:PERAMIVIRMemberus-gaap:ProductMember2021-01-012021-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2022-04-012022-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2021-04-012021-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2022-01-012022-06-300000882796bcrx:CollaborativeAndOtherResearchAndDevelopmentMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2021-01-012021-06-300000882796us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300000882796us-gaap:CorporateDebtSecuritiesMember2022-06-300000882796us-gaap:CertificatesOfDepositMember2022-06-300000882796us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000882796us-gaap:CorporateDebtSecuritiesMember2021-12-310000882796us-gaap:CertificatesOfDepositMember2021-12-310000882796bcrx:ORLADEYOMemberus-gaap:TradeAccountsReceivableMember2022-06-300000882796bcrx:ORLADEYOMemberus-gaap:TradeAccountsReceivableMember2021-12-310000882796bcrx:RAPIVABMemberus-gaap:TradeAccountsReceivableMember2022-06-300000882796bcrx:RAPIVABMemberus-gaap:TradeAccountsReceivableMember2021-12-310000882796us-gaap:TradeAccountsReceivableMember2021-12-310000882796us-gaap:TradeAccountsReceivableMember2022-06-300000882796us-gaap:BilledRevenuesMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2022-06-300000882796us-gaap:UnbilledRevenuesMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2022-06-300000882796bcrx:USDepartmentOfHealthAndHumanServicesMember2022-06-300000882796us-gaap:BilledRevenuesMemberbcrx:RoyaltyReceivablesFromPartnersMember2022-06-300000882796us-gaap:UnbilledRevenuesMemberbcrx:RoyaltyReceivablesFromPartnersMember2022-06-300000882796bcrx:RoyaltyReceivablesFromPartnersMember2022-06-300000882796us-gaap:BilledRevenuesMember2022-06-300000882796us-gaap:UnbilledRevenuesMember2022-06-300000882796us-gaap:BilledRevenuesMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2021-12-310000882796us-gaap:UnbilledRevenuesMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2021-12-310000882796bcrx:USDepartmentOfHealthAndHumanServicesMember2021-12-310000882796us-gaap:BilledRevenuesMemberbcrx:RoyaltyReceivablesFromPartnersMember2021-12-310000882796us-gaap:UnbilledRevenuesMemberbcrx:RoyaltyReceivablesFromPartnersMember2021-12-310000882796bcrx:RoyaltyReceivablesFromPartnersMember2021-12-310000882796us-gaap:BilledRevenuesMember2021-12-310000882796us-gaap:UnbilledRevenuesMember2021-12-310000882796bcrx:GreenCrossCorporationMemberus-gaap:TradeAccountsReceivableMember2021-12-310000882796bcrx:GreenCrossCorporationMemberus-gaap:TradeAccountsReceivableMember2022-06-300000882796bcrx:JPRRoyaltySubLLCMemberbcrx:RoyaltyMonetizationMember2011-03-090000882796bcrx:JPRRoyaltySubLLCMemberbcrx:RoyaltyMonetizationMember2011-03-012011-03-090000882796bcrx:JPRRoyaltySubLLCMemberbcrx:PhaRMANotesMember2011-03-012011-03-090000882796bcrx:JPRRoyaltySubLLCMemberbcrx:PhaRMANotesMember2011-03-09xbrli:pure0000882796bcrx:JPRRoyaltySubLLCMemberbcrx:PhaRMANotesMember2020-12-010000882796bcrx:JPRRoyaltySubLLCMemberus-gaap:FairValueInputsLevel2Memberbcrx:PhaRMANotesMember2021-12-310000882796bcrx:JPRRoyaltySubLLCMemberbcrx:PhaRMANotesMember2021-01-012021-12-310000882796bcrx:FutureRoyaltiesPayableMemberbcrx:RPI2019IntermediateFinanceTrustMember2020-12-072020-12-070000882796bcrx:AnnualNetSalesUnder350000Memberbcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:AnnualNetSalesBetween350000And550000Memberbcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:AnnualNetSalesOver550000Memberbcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:BCX9930Memberbcrx:RPI2019IntermediateFinanceTrustMember2020-12-072020-12-070000882796bcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:AnnualNetSalesUnder150000Memberbcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:RPI2019IntermediateFinanceTrustMemberbcrx:AnnualNetSalesBetween150000And230000Memberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:AnnualNetSalesOver230000Memberbcrx:RPI2019IntermediateFinanceTrustMemberbcrx:ORLADEYOMember2020-12-072020-12-070000882796bcrx:RPI2021And2020IntermediateFinanceTrustMemberbcrx:FutureRoyaltiesPayableMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesUnder350000Memberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesBetween350000And550000Memberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesUnder150000Memberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesBetween150000And230000Memberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:BCX9930Memberbcrx:The2021RPIRoyaltyPurchaseAgreementMemberbcrx:AnnualNetSalesUnder15BillionMember2021-11-192021-11-190000882796bcrx:BCX9930Memberbcrx:AnnualNetSalesBetween15And3BillionsMemberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:BCX9930Memberbcrx:AnnualNetSalesOver3BillionsMemberbcrx:The2021RPIRoyaltyPurchaseAgreementMember2021-11-192021-11-190000882796bcrx:BCX9930Memberbcrx:AnnualNetSalesOver3BillionsMemberbcrx:RPI2019IntermediateFinanceTrustMember2021-11-192021-11-190000882796bcrx:BCX9930Memberbcrx:RPI2019IntermediateFinanceTrustMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesUnder350000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesBetween350000And550000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesOver550000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesUnder350000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-190000882796bcrx:AnnualNetSalesBetween350000And550000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-190000882796bcrx:AnnualNetSalesOver550000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-190000882796bcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:AnnualNetSalesUnder150000Memberbcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:OMERSCapitalMarketsMemberbcrx:AnnualNetSalesBetween150000And230000Memberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:OMERSCapitalMarketsMemberbcrx:AnnualNetSalesOver230000Memberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMembersrt:MinimumMember2021-11-192021-11-190000882796bcrx:OMERSCapitalMarketsMembersrt:MaximumMemberbcrx:ORLADEYOMember2021-11-192021-11-190000882796bcrx:OMERSCapitalMarketsMemberbcrx:ORLADEYOMember2021-11-190000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2022-03-310000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2022-06-300000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2022-03-310000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2022-06-300000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2021-12-310000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2021-12-310000882796bcrx:OMERSRoyaltyAgreementMember2021-12-310000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2021-01-012021-03-310000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2021-01-012021-03-310000882796bcrx:OMERSRoyaltyAgreementMember2021-01-012021-03-310000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2022-01-012022-03-310000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2022-01-012022-03-310000882796bcrx:OMERSRoyaltyAgreementMember2022-01-012022-03-310000882796bcrx:OMERSRoyaltyAgreementMember2022-03-310000882796bcrx:TwentyTwentyRPIRoyaltyAgreementMember2022-04-012022-06-300000882796bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember2022-04-012022-06-300000882796bcrx:OMERSRoyaltyAgreementMember2022-04-012022-06-300000882796bcrx:OMERSRoyaltyAgreementMember2022-06-300000882796bcrx:FutureRoyaltiesPayableMemberbcrx:RPI2019IntermediateFinanceTrustMember2022-06-300000882796bcrx:RPI2019IntermediateFinanceTrustMember2022-06-300000882796bcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-070000882796bcrx:TermALoanMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796bcrx:SeniorCreditFacilityMemberbcrx:MidCapFinancialServicesLLCMember2020-12-072020-12-070000882796us-gaap:SubsequentEventMemberbcrx:AthyriumMemberbcrx:TermBLoanMemberbcrx:CreditAgreementMember2022-07-290000882796us-gaap:SubsequentEventMemberbcrx:AthyriumMemberbcrx:CreditAgreementMemberbcrx:TermCLoanMember2022-07-290000882796us-gaap:SubsequentEventMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2022-07-290000882796us-gaap:LondonInterbankOfferedRateLIBORMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796us-gaap:LondonInterbankOfferedRateLIBORMemberbcrx:PikInterestPaymentIsMadeMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796us-gaap:LondonInterbankOfferedRateLIBORMemberbcrx:PikInterestPaymentIsMadeMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2022-06-282022-06-280000882796bcrx:PriorToTheSecondAnniversaryMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796bcrx:BetweenTheSecondAndThirdAnniversariesMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796bcrx:BetweenTheThirdAndFourthAnniversariesMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796bcrx:AfterFourthAnniversaryMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-072020-12-070000882796bcrx:TermLoanADrawnMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-070000882796bcrx:AthyriumMemberbcrx:TermLoanAAndBDrawnMemberbcrx:CreditAgreementMember2020-12-070000882796bcrx:TermLoansABAndCDrawnMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-070000882796bcrx:TermLoansABAndCDrawnAndCureRightExercisedMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2020-12-070000882796bcrx:AthyriumMemberbcrx:CreditAgreementMember2022-06-300000882796bcrx:AthyriumMemberbcrx:CreditAgreementMember2022-01-012022-06-300000882796bcrx:AthyriumMemberbcrx:CreditAgreementMember2021-01-012021-06-300000882796bcrx:TermALoanMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2022-06-300000882796bcrx:TermALoanMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2022-01-012022-06-300000882796bcrx:TermALoanMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2021-01-012021-06-300000882796srt:MinimumMember2022-06-300000882796srt:MaximumMember2022-06-300000882796us-gaap:OtherAssetsMember2022-06-300000882796us-gaap:OtherAssetsMember2021-12-310000882796bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember2022-06-3000008827962020-04-240000882796bcrx:CommonStockPurchaseAgreementWithRPIMember2021-11-192021-11-190000882796bcrx:CommonStockPurchaseAgreementWithRPIMember2021-11-190000882796bcrx:CommonStockPurchaseAgreementWithRPIMember2021-11-17bcrx:plan0000882796bcrx:IncentivePlanMember2022-01-012022-06-300000882796bcrx:InducementPlanMember2022-01-012022-06-300000882796bcrx:EmployeeStockPurchasePlanMember2022-01-012022-06-300000882796bcrx:IncentivePlanMember2021-01-012021-06-300000882796bcrx:InducementPlanMember2021-01-012021-06-300000882796bcrx:EmployeeStockPurchasePlanMember2021-01-012021-06-300000882796bcrx:Vest25PercentEachYearUntilFullyVestedMemberbcrx:IncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:IncentivePlanMemberus-gaap:PerformanceSharesMemberbcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember2014-12-012014-12-310000882796bcrx:PerformancebasedRestrictedStockUnitsMemberbcrx:IncentivePlanMemberbcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember2022-01-012022-01-310000882796us-gaap:ShareBasedCompensationAwardTrancheOneMemberbcrx:PerformancebasedRestrictedStockUnitsMemberbcrx:IncentivePlanMember2022-01-012022-01-310000882796bcrx:Vest25PercentEachYearUntilFullyVestedMemberbcrx:PerformancebasedRestrictedStockUnitsMemberbcrx:IncentivePlanMember2022-01-012022-01-310000882796bcrx:IncentivePlanMemberbcrx:ThirtysixEqualMonthlyInstallmentsMemberbcrx:NonEmployeeDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:NonEmployeeDirectorsMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:PerformancebasedRestrictedStockUnitsMemberbcrx:IncentivePlanMember2022-01-012022-01-310000882796srt:MaximumMemberbcrx:IncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:IncentivePlanMember2021-12-310000882796bcrx:IncentivePlanMember2022-06-300000882796bcrx:IncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:IncentivePlanMemberus-gaap:EmployeeStockOptionMember2021-01-012021-06-300000882796us-gaap:RestrictedStockUnitsRSUMemberbcrx:IncentivePlanMember2022-01-012022-06-300000882796us-gaap:RestrictedStockUnitsRSUMemberbcrx:IncentivePlanMember2021-01-012021-06-300000882796bcrx:Vest25PercentEachYearUntilFullyVestedMemberbcrx:InducementPlanMember2022-01-012022-06-300000882796bcrx:InducementPlanMember2021-12-310000882796bcrx:InducementPlanMember2022-06-300000882796us-gaap:RestrictedStockUnitsRSUMemberbcrx:InducementPlanMember2022-01-012022-06-300000882796bcrx:InducementPlanMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300000882796bcrx:IncentivePlanAndInducementPlanMember2022-01-012022-06-300000882796bcrx:IncentivePlanAndInducementPlanMember2021-01-012021-06-300000882796bcrx:EmployeeStockPurchasePlanMember2022-06-300000882796bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember2021-09-152021-09-150000882796bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember2013-09-302013-09-300000882796bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember2020-08-012020-08-310000882796bcrx:BaseContractMember2015-06-300000882796bcrx:AdditionalDevelopmentOptionsMember2015-06-300000882796bcrx:ASPRBARDAContractMember2015-06-300000882796bcrx:ASPRBARDAContractMember2022-01-012022-06-300000882796bcrx:USDepartmentOfHealthAndHumanServicesMember2018-09-062018-09-060000882796bcrx:RAPIVABMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2018-09-062018-09-06bcrx:dose0000882796bcrx:RAPIVABMemberbcrx:USDepartmentOfHealthAndHumanServicesMember2022-01-012022-06-300000882796bcrx:ToriiPharmaceuticalCoMember2019-11-052019-11-050000882796bcrx:ToriiPharmaceuticalCoMember2019-11-050000882796bcrx:ToriiPharmaceuticalCoMembersrt:MinimumMember2019-11-050000882796srt:MaximumMemberbcrx:ToriiPharmaceuticalCoMember2019-11-050000882796bcrx:AECOMAndIRLMember2000-06-012000-06-300000882796bcrx:AECOMAndIRLMember2000-09-300000882796bcrx:UABMember2022-01-012022-06-300000882796us-gaap:SubsequentEventMemberbcrx:AthyriumMemberbcrx:CreditAgreementMember2022-07-292022-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________________ to ______________________
Commission File Number 000-23186
BIOCRYST PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware62-1413174
(State or other jurisdiction of(I.R.S. Employer
incorporation or organization)Identification No.)
4505 Emperor Blvd., Suite 200
Durham, North Carolina
27703
(Address of principal executive offices)(Zip Code)
+1-919-859-1302
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBCRXNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
o
  Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of July 29, 2022 was 185,945,016.


BIOCRYST PHARMACEUTICALS, INC.
INDEX
Page No.


When used in this report, unless otherwise indicated, we, our, us, the Company, and BioCryst refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “report”) includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of this report, as well as any amendments we make to those sections in filings with the Securities and Exchange Commission (“SEC”). These forward-looking statements include, but are not limited to, statements about:
the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO® (berotralstat), BCX9930, BCX9250, peramivir, galidesivir, and early-stage discovery programs, and our plans regarding the same;
the timing and success of our commercialization of ORLADEYO in the United States and elsewhere and expectations regarding the commercial market for ORLADEYO;
the potential for government stockpiling orders of our products and product candidates, including the timing or likelihood of entering into any U.S. Government stockpile order and our ability to execute any such order;
the potential funding from our contracts with the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (“BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases within the HHS (“NIAID/HHS”) for the development of galidesivir;
additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners;
the implementation of our business model, strategic plans for our business, products, product candidates and technology;
our ability to establish and maintain collaborations or out-license rights to our products and product candidates;
plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd. (“Torii”) for ORLADEYO in Japan and Shionogi & Co., Ltd. (“Shionogi”) and Green Cross Corporation (“Green Cross”) for peramivir in their territories;
our and our subsidiary guarantors’ ability to satisfy obligations under our Credit Agreement (as defined below) and to comply with the covenants as set forth in the agreements governing our debt obligations;
the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates, and technology;
our ability to operate our business without infringing the intellectual property rights of others;
estimates of our revenues, expenses, capital requirements, annual cash utilization, and our needs for additional financing;
the timing or likelihood of regulatory filings or regulatory agreements, deferrals, approvals, and other decisions;
our ability to manage our liquidity needs, including our ability to raise additional capital, to fund our operations or repay our recourse debt obligations;
our financial performance; and
i

competitive companies, technologies, and our industry.
We have based any forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from those suggested or implied by these forward-looking statements for various reasons, including those discussed in this report under the heading “Risk Factors” in Part II, Item 1A, some of which are summarized in the “Risk Factor Summary” below. Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future events or developments, except as may be required by U.S. federal securities laws.
Risk Factor Summary
An investment in the Company involves risks. You should carefully read this entire report and consider the uncertainties and risks discussed in the “Risk Factors” section in Part II, Item 1A of this report, which may adversely affect our business, financial condition, or results of operations, along with the other information included in our other filings with the SEC, before making an investment decision in the Company. A summary of the principal factors that make an investment in the Company speculative or risky is set forth below.
The ongoing novel coronavirus (“COVID-19”) pandemic could create challenges in all aspects of our business, including, without limitation, delays, stoppages, difficulties, and increased expenses with respect to our and our partners’ development, regulatory processes, and supply chains, negatively impact our ability to access the capital or credit markets to finance our operations, or have the effect of heightening many of the risks described below or in the “Risk Factors” section in Part II, Item 1A of this report.
We have incurred losses since our inception, expect to continue to incur losses, and may never be profitable.
We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.
Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, to receive and maintain regulatory approval for the commercial sale of our product candidates, and to successfully commercialize any approved products. The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective. For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, or take other actions that could materially impact the cost, timing, and success of our planned development strategies.
We rely heavily upon third parties, including development partners, contractors, contract research organizations, and third-party suppliers, manufacturers, and distributors, for many important stages of our product candidate development and in the commercialization of certain of our products and product candidates. Our failure to establish and maintain these relationships, the failure of any such third party to perform its obligations under agreements with us, or the failure of such a relationship to meet our expectations could have a material adverse impact on our business, financial condition, and results of operations.
If we fail to obtain additional financing or acceptable partnership arrangements as and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.
The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.
There can be no assurance that our or our partners’ commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.
ii

We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties managing our growth, which could disrupt our operations.
We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced. In addition, developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.
We are subject to various laws and regulations related to our products and product candidates, and if we or our employees, consultants, or partners do not comply with these laws and regulations, we could face substantial penalties and our reputation could be harmed. In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners’ ability to market and develop our products and product candidates, obtain collaborators, and raise capital.
If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish. Legal proceedings to protect or enforce our patents, the patents of our partners, or our other intellectual property rights could be expensive, time consuming, and unsuccessful.
We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death, and our product liability insurance coverage may be insufficient.
We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts.
If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.
Our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness under the Credit Agreement earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.
International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks. For example, our actual or perceived failure to comply with European governmental laws and regulations and other obligations related to privacy, data protection, and information security could harm our business. In addition, the United Kingdom’s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.
If our facilities incur damage or power is lost for a significant length of time, our business will suffer.
A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.
Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interests of other stockholders.
Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.
Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest, or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators, or third parties with whom we conduct business now or in the future.
We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.
iii

If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped.
iv

PART I. FINANCIAL INFORMATION
Item 1.    Financial Statements
BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
June 30, 2022 and December 31, 2021
(In thousands, except per share data)
20222021
(Unaudited)(Note 1)
Assets
Cash and cash equivalents$272,571 $504,389 
Restricted cash1,448 3,345 
Investments144,912 3,212 
Trade receivables41,491 29,413 
Inventory23,378 15,791 
Prepaid expenses and other current assets11,053 9,986 
Total current assets494,853 566,136 
Property and equipment, net8,702 8,714 
Long-term investments 6,829 
Other assets6,983 6,472 
Total assets$510,538 $588,151 
Liabilities and Stockholders’ Deficit
Accounts payable$12,024 $27,808 
Accrued expenses79,711 72,670 
Deferred revenue1,521 1,421 
Lease financing obligation2,134 1,819 
Total current liabilities95,390 103,718 
Lease financing obligation6,198 5,962 
Royalty financing obligations477,666 449,375 
Secured term loan144,516 136,082 
Stockholders’ equity:  
Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding
  
Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding – 185,876 as of June 30, 2022 and 184,350 as of December 31, 2021
1,859 1,843 
Additional paid-in capital1,125,453 1,098,498 
Accumulated other comprehensive income15 177 
Accumulated deficit(1,340,559)(1,207,504)
Total stockholders’ deficit(213,232)(106,986)
Total liabilities and stockholders’ deficit$510,538 $588,151 
See accompanying notes to consolidated financial statements.
1

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Three and Six Months Ended June 30, 2022 and 2021
(In thousands, except per share data-Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenues
Product sales, net$64,888 $33,430 $114,434 $51,301 
Royalty revenue540 128 887 (769)
Milestone revenue 15,000  15,000 
Collaborative and other research and development104 1,401 134 3,486 
Total revenues65,532 49,959 115,455 69,018 
Expenses  
Cost of product sales246 297 482 6,220 
Research and development61,990 52,873 127,350 95,308 
Selling, general and administrative38,017 26,325 72,299 48,439 
Royalty1 46 3 10 
Total operating expenses100,254 79,541 200,134 149,977 
Loss from operations(34,722)(29,582)(84,679)(80,959)
Interest and other income609 13 663 39 
Interest expense(24,022)(13,495)(47,859)(26,399)
Foreign currency gains (losses), net132 (134)(45)(163)
Loss before income taxes(58,003)(43,198)(131,920)(107,482)
Income tax expense856  1,135  
Net loss$(58,859)$(43,198)$(133,055)$(107,482)
Foreign currency translation adjustment104 (92)182 86 
Unrealized loss on available for sale investments(275)(3)(344)(2)
Comprehensive loss$(59,030)$(43,293)$(133,217)$(107,398)
  
Basic and diluted net loss per common share$(0.32)$(0.24)$(0.72)$(0.60)
Weighted average shares outstanding185,605 178,127 185,253 177,737 
See accompanying notes to consolidated financial statements.
2

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended June 30, 2022 and 2021
(In thousands-Unaudited)
Six Months Ended June 30,
20222021
Cash flows from operating activities:
Net loss$(133,055)$(107,482)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation and amortization652 377 
Stock-based compensation expense19,468 13,111 
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs36,725 22,664 
Amortization of premium/discount on investments(88)34 
Changes in operating assets and liabilities:  
Receivables(12,343)(18,976)
Inventory(7,589)(2,809)
Prepaid expenses and other assets(1,050)(34)
Accounts payable and accrued expenses(8,463)2,743 
Interest payable 3,547 
Deferred revenue186 403 
Net cash used in operating activities(105,557)(86,422)
  
Cash flows from investing activities:  
Acquisitions of property and equipment(650)(912)
Purchase of investments(139,260) 
Sales and maturities of investments4,000 20,089 
Net cash (used in) provided by investing activities(135,910)19,177 
  
Cash flows from financing activities:  
Net proceeds from common stock issued under stock-based compensation plans7,503 7,474 
Net cash provided by financing activities7,503 7,474 
Effect of exchange rate on cash, cash equivalents, and restricted cash249 85 
  
Decrease in cash, cash equivalents and restricted cash(233,715)(59,686)
Cash, cash equivalents and restricted cash at beginning of period507,734 274,348 
Cash, cash equivalents and restricted cash at end of period$274,019 $214,662 
See accompanying notes to consolidated financial statements.
3

BIOCRYST PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT
Three and Six Months Ended June 30, 2022 and 2021
(In thousands, except per share amounts-Unaudited)
Common
Stock
Additional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stockholders’
Deficit
Balance at December 31, 2021$1,843 $1,098,498 $177 $(1,207,504)$(106,986)
Net loss— — — (74,196)(74,196)
Other comprehensive income— — 9 — 9 
Employee stock purchase plan sales, 115 shares, net
1 1,503 — — 1,504 
Exercise of stock options, 1,108 shares, net
12 5,841 — — 5,853 
Stock-based compensation expense— 9,601 — — 9,601 
Balance at March 31, 2022$1,856 $1,115,443 $186 $(1,281,700)$(164,215)
Net loss— — — (58,859)(58,859)
Other comprehensive income— — (171)— (171)
Exercise of warrants, 253 shares
3 — — — 3 
Exercise of stock options, 51 shares, net
— 145 — — 145 
Stock-based compensation expense— 9,865 — — 9,865 
Balance at June 30, 2022$1,859 $1,125,453 $15 $(1,340,559)$(213,232)
Common
Stock
Additional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stockholders’
Deficit
Balance at December 31, 2020$1,769 $1,002,408 $3 $(1,023,442)$(19,262)
Net loss— — — (64,284)(64,284)
Other comprehensive income— — 179 — 179 
Employee stock purchase plan sales, 193 shares, net
2 721 — — 723 
Exercise of stock options, 593 shares, net
6 2,171 — — 2,177 
Stock-based compensation expense— 5,479 — — 5,479 
Balance at March 31, 2021$1,777 $1,010,779 $182 $(1,087,726)$(74,988)
Net loss— — — (43,198)(43,198)
Other comprehensive income— — (95)— (95)
Exercise of stock options, 1,056 shares, net
10 4,564 — — 4,574 
Stock-based compensation expense— 7,632 — — 7,632 
Balance at June 30, 2021$1,787 $1,022,975 $87 $(1,130,924)$(106,075)
See accompanying notes to consolidated financial statements.
4


BIOCRYST PHARMACEUTICALS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands, except per share amounts)
(Unaudited)
Note 1 Significant Accounting Policies and Concentrations of Risk
The Company
BioCryst Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in 1986 and incorporated in Delaware in 1991, and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.
The Company’s marketed products include oral, once-daily ORLADEYO® for the prevention of hereditary angioedema (“HAE”) attacks and RAPIVAB® (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. ORLADEYO received regulatory approval in the United States in December 2020. ORLADEYO has also received regulatory approvals in multiple global markets. The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company’s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company. In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.
Based on the Company’s expectations for revenue and operating expenses, the Company believes its financial resources available at June 30, 2022 will be sufficient to fund its operations for at least the next 12 months. The Company has sustained operating losses for the majority of its corporate history and expects that its 2022 expenses will exceed its 2022 revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company’s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (2) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change its overhead structure. The Company may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events and its decisions in the future.
Basis of Presentation
The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.
The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the Company’s consolidated financial position, results of operations, and cash flows. There were no adjustments other than normal recurring adjustments.
These financial statements should be read in conjunction with the financial statements for the year ended December 31, 2021 and the notes thereto included in the Company’s 2021 Annual Report on Form 10-K. Interim operating
5

results are not necessarily indicative of operating results for the full year. The balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements included in the Company’s most recent Annual Report on Form 10-K.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Revenue Recognition
Pursuant to Accounting Standards Codification (“ASC”) Topic 606, the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.
At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.
Product Sales, Net
The Company’s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in December 2020, sales of peramivir to the Company’s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (“HHS”) under the Company’s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.
The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.
Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.
Government and Managed Care Rebates. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the
6

establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.
Chargebacks. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company’s specialty pharmacy. These customers purchase the Company’s product under contracts negotiated between them and the Company’s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy’s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.
Co-payment assistance and patient assistance programs. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient’s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.
Product returns. The Company does not provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.
Collaborative and Other Research and Development Arrangements and Royalties
The Company has collaboration and license agreements with a number of third parties, as well as research and development agreements with certain government entities. The Company’s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.
Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.
Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.
Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement;
7

and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.
Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company’s contracts with the Biomedical Advanced Research and Development Authority within the HHS (“BARDA/HHS”) and the National Institute of Allergy and Infectious Diseases (“NIAID/HHS”), revenue is recognized as reimbursable direct and indirect costs are incurred.
Under certain of the Company’s license agreements, the Company receives royalty payments based upon its licensees’ net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.
Cash and Cash Equivalents
The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of three months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.
Restricted Cash
Restricted cash of $24 and $1,924 as of June 30, 2022 and December 31, 2021, respectively, reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note 6). Additionally, restricted cash of $1,424 and $1,421 as of June 30, 2022 and December 31, 2021, respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.
Investments
The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company’s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company’s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of three years and requires an average portfolio maturity of no more than 12 months. Some of the securities in which the Company invests may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does not believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company’s investments are not collateralized. The Company has not realized any significant losses from its investments.
The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond three months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At June 30, 2022, the Company believes that the cost of its investments is recoverable in all material respects.
8

Trade Receivables
The majority of the Company’s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other third-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within 30 to 90 days.
Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company’s partners, including Shionogi, Green Cross, and Torii.
Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company’s calculations of its indirect cost rates are subject to audit by the U.S. Government.
The Company does not adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in one year or less from the time of sale.
The Company provides reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company’s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.
The Company’s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company may experience spoilage of its raw materials and supplies. The Company’s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.
The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.
Property and Equipment
Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of three years. Laboratory equipment, office equipment, and software are depreciated over a life of five years. Furniture and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.
In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
9

Accrued Expenses
The Company generally enters into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (“CROs”) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company’s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.
The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of June 30, 2022 and December 31, 2021, the carrying value of accrued expenses approximates their fair value due to their short-term settlement.
Cost of Product Sales
Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales may also include costs related to excess or obsolete inventory adjustment charges.
Research and Development Expenses
The Company’s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company’s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company’s manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company’s ongoing review of the level of services actually performed.
Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (“AECOM”), Industrial Research, Ltd. (“IRL”), and the University of Alabama at Birmingham (“UAB”), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.
Deferred collaboration expenses represent sub-license payments, paid to the Company’s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company’s academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from the Company’s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.
10

Selling, General and Administrative Expenses
Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.
Advertising expenses related to ORLADEYO were $4,095 and $8,079 for the three and six months ended June 30, 2022, respectively, and $1,800 and $3,204 for the three and six months ended June 30, 2021, respectively.
The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.
Leases
The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of June 30, 2022. The Company accounts for lease obligations in accordance with ASU 2016-02: Leases (Topic 842), which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.
Certain of the Company’s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company’s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that the Company is likely to exercise. As part of the Company’s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of twelve months or less was not material.
The discount rate used in the calculation of the Company’s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company’s collateralized borrowing rate from lending institutions.
The Company has not made any residual value guarantees related to its operating leases; therefore, the Company has no corresponding liability recorded on its Consolidated Balance Sheets.
Stock-Based Compensation
All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company’s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, the Company has outstanding performance-based stock options for which no compensation expense is recognized until “performance” is deemed to have occurred.
Interest Expense and Deferred Financing Costs
Interest expense for the three and six months ended June 30, 2022 was $24,022 and $47,859, respectively, and $13,495 and $26,399 for the three and six months ended June 30, 2021, respectively, and primarily relates to the royalty financing obligations (Note 6), the secured term loan borrowing from the Credit Agreement (Note 7) and the PhaRMA Notes (Note 6). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(172) and $(339) for the three and six months ended June 30, 2022, respectively, and $(154) and $(211) for the three and six months ended June 30, 2021, respectively.
In December 2021, the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to “Note 6—Royalty Monetizations—RAPIACTA—Non-Recourse Notes Payable – Debt Extinguishment” for additional information regarding the debt extinguishment).
11

Interest Expense and Royalty Financing Obligations
The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.
Income Taxes
The liability method is used in the Company’s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.
Beginning in fiscal year 2021, the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had no presence.
Net Loss Per Share
Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company’s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share does not include 23,090 and 25,877 shares of potential common stock for the three and six months ended June 30, 2022, respectively, and 27,419 and 25,871 shares of potential common stock for the three and six months ended June 30, 2021, respectively, as their impact would be anti-dilutive.
Accumulated Other Comprehensive Income
Accumulated other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders’ equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the six months ended June 30, 2022. For the six months ended June 30, 2021, realized gains of $1 were reclassified out of accumulated other comprehensive loss.
Significant Customers and Other Risks
Significant Customers
The Company’s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly BCX4430) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under the Company's procurement contract with the Assistant Secretary for Preparedness and Response within HHS.
ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy’s inability or unwillingness to continue these distribution activities could adversely impact the Company’s business, results of operations and financial condition.
12

The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company’s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company’s business, results of operations and financial condition.
Further, the Company’s drug development activities are performed by a limited group of third-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company’s ability to complete its drug development activities.
Risks from Third-Party Manufacturing and Distribution Concentration
The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company’s product candidates.
Credit Risk
Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances may exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 12 months or less.
The Company’s receivables from sales of ORLADEYO are primarily due from one customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from one of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.
The majority of the Company’s receivables from collaborations are due from the U.S. Government, for which there is no assumed credit risk.
Recently Adopted Accounting Pronouncements
There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the six months ended June 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, that the Company believes are of significance or potential significance to the Company.
13

Note 2 Revenue
The Company recorded the following revenues (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Product sales, net:
ORLADEYO$64,711 $28,374 $114,097 $39,312 
RAPIVAB177 4,622 337 4,735 
Peramivir 434  7,254 
Total product sales, net64,888 33,430 114,434 51,301 
Royalty revenue540 128 887 (769)
Milestone revenue 15,000  15,000 
Collaborative and other research and development revenues:  
U.S. Department of Health and Human Services104 1,401 134 3,486 
Total collaborative and other research and development revenues104 1,401 134 3,486 
Total revenues$65,532 $49,959 $115,455 $69,018 
Note 3 Investments
The following tables summarize the fair value of the Company’s investments by type. The estimated fair values of the Company’s fixed income investments are classified as Level 2 in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but not identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. These fair values are obtained from independent pricing services which utilize Level 2 inputs.
June 30, 2022
Amortized
Cost
Accrued
Interest
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
Obligations of U.S. Government and its agencies$137,222 $135 $2 $(393)$136,966 
Corporate debt securities6,299 47  (38)6,308 
Certificates of deposit1,644 8  (14)1,638 
Total investments$145,165 $190 $2 $(445)$144,912 
December 31, 2021
Amortized
Cost
Accrued
Interest
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
Obligations of U.S. Government and its agencies$4,043 $17 $ $(7)$4,053 
Corporate debt securities4,294 40  (5)4,329 
Certificates of deposit1,652 8  (1)1,659 
Total investments$9,989 $65 $ $(13)$10,041 
14

The following table summarizes the scheduled maturity for the Company’s investments at June 30, 2022 and December 31, 2021:
June 30, 2022December 31, 2021
Maturing in one year or less$144,912 $3,212 
Maturing after one year through two years 6,829 
Total investments$144,912 $10,041 

Note 4 Trade Receivables
Product Sales
Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At June 30, 2022 and December 31, 2021, receivables related to sales of ORLADEYO were $39,587 and $27,384, respectively. At June 30, 2022 and December 31, 2021, receivables related to sales of RAPIVAB were $61 and $49, respectively. No reserve or allowance amounts were recorded as of June 30, 2022 and December 31, 2021, respectively.
Collaborations
Receivables from collaborations were as follows (in thousands):
June 30, 2022
BilledUnbilledTotal
U.S. Department of Health and Human Services$ $1,303 $1,303 
Royalty receivables from partners540  540 
Total receivables$540 $1,303 $1,843 
December 31, 2021
BilledUnbilledTotal
U.S. Department of Health and Human Services$5 $1,670 $1,675 
Royalty receivables from partners305  305 
Total receivables$310 $1,670 $1,980 
As of both June 30, 2022 and December 31, 2021, the Company maintained a reserve of $701 related to royalties associated with Green Cross.
Note 5 Inventory
At June 30, 2022 and December 31, 2021, the Company’s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company’s partners.
The Company’s inventories consisted of the following (in thousands):
June 30, 2022December 31, 2021
Raw materials$5,276 $5,658 
Work-in-process15,616 9,669 
Finished goods2,739 709 
Total inventory$23,631 $16,036 
Reserves(253)(245)
Total inventory, net$23,378 $15,791 
15

Note 6 Royalty Monetizations
RAPIACTA
Overview
On March 9, 2011, the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company’s agreement with Shionogi (the “Shionogi Agreement”), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (“Royalty Sub”), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the September 2012 interest payment.
As part of the transaction, the Company entered into a purchase and sale agreement dated as of March 9, 2011 with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the “Currency Hedge Agreement”) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company’s collaboration with Shionogi was not impacted as a result of this transaction.
Non-Recourse Notes Payable
On March 9, 2011, Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on December 1, 2020 (the “PhaRMA Notes”). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of March 9, 2011 (the “Indenture”), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on September 1st of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.
Royalty Sub’s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company’s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company may, but is not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.
In September 2014, Royalty Sub was unable to pay the accrued interest obligation due September 3, 2013. Under the terms of the Indenture, Royalty Sub’s inability to pay the full amount of interest payable in September 2013 by the next succeeding payment date for the PhaRMA Notes, which was September 1, 2014, constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the December 31, 2014 balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes may foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full.
Non-Recourse Notes Payable – Debt Extinguishment
During 2021, the royalty-bearing patents associated with RAPIACTA in Japan expired. Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since September 1, 2014 and the legal maturity on December 1, 2020 and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is
16

predicated. As a result, the Company determined that it was no longer the financial obligor, and as a result, the principal balance of $30,000 and associated accrued interest payable balance of $25,838 were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended December 31, 2021.
ORLADEYO and Factor D Inhibitors
On December 7, 2020, the Company and RPI 2019 Intermediate Finance Trust (“RPI”) entered into a Purchase and Sale Agreement (the “2020 RPI Royalty Purchase Agreement”), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the “2020 RPI Royalty Sale”). Under the 2020 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the “Key Territories”), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the “Direct Sales”) in an amount equal to: (i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 2.75% of annual net sales for annual net sales between $350,000 and $550,000. No royalty payments are payable on annual Direct Sales over $550,000. In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of BCX9930.
Under the 2020 RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the “Other Markets”) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to $150,000 in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.
On November 19, 2021, the Company and RPI entered into (i) a Purchase and Sale Agreement (the “2021 RPI Royalty Purchase Agreement” and together with the 2020 RPI Royalty Purchase Agreement, the “RPI Royalty Purchase Agreements”), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000 in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (“OMERS”) (the “OMERS Royalty Purchase Agreement” and collectively with the RPI Royalty Purchase Agreements, the “Royalty Purchase Agreements”), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional $150,000 in cash.
Under the 2021 RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 1.75% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000. No royalty payments are payable on Direct Sales over $550,000. RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to 3.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 2.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets.
Under the 2021 RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of BCX9930 and another earlier stage Factor D inhibitor in an amount equal to: (i) 3.0% of worldwide aggregate annual net sales up to $1.5 billion and (ii) 2.0% of worldwide aggregate annual net sales between $1.5 billion and $3.0 billion. No royalty payments are payable on annual net sales above $3.0 billion. RPI is also entitled to receive tiered profit share amounts of up to 3.0% from certain other permitted sales in certain other markets.
The royalties payable under the 2021 RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the 2020 RPI Royalty Purchase Agreement.
Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning October 1, 2023, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 6.0% of annual net sales of ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the “Regime A Royalty Rate”). If annual Direct Sales for calendar year 2023 reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after January 1, 2024, OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year 2023 are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i) 10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to $350,000 and (ii) 3.0% of annual net sales of
17

ORLADEYO for annual net sales between $350,000 and $550,000 (with no royalty payments payable on annual Direct Sales over $550,000) (the “Regime B Royalty Rate”).
Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i) 20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii) 20.0% of proceeds received by the Company on annual net sales of up to $150,000 in the Other Markets, and (iii) 10.0% of proceeds received by the Company on annual net sales between $150,000 and $230,000 in the Other Markets. No royalty payments are payable on annual net sales above $230,000 in the Other Markets. OMERS is also entitled to receive profit share amounts of up to 10% from certain other permitted sales in certain other markets.
Under the 2020 RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the first commercial sale of ORLADEYO in any country. Under the 2021 RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2021. Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after October 1, 2023. OMERS will no longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either 142.5% or 155.0% of the $150,000 purchase price, depending on sales levels in calendar year 2023.
The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the “Royalty Sales”.
Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, third-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company’s Credit Agreement with Athyrium Opportunities III Co-Invest 1 LP. Refer to Note 7 for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.
The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in “Royalty financing obligations” on the Company’s consolidated balance sheet. The fair value for the royalty financing obligations at the time of the transactions was based on the Company’s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate.
During the three months ended June 30, 2022, the Company adjusted its forecasts related to its Factor D program. Accordingly, this impacted the amount and timing of expected royalties to be made under the RPI Royalty Purchase Agreements. As a result, the effective interest rate related to the 2020 RPI Royalty Purchase Agreement decreased from 27.3% to 25.5%, and the effective interest rate related to the 2021 RPI Royalty Purchase Agreement decreased from 16.5% to 12.1%.
18

The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of June 30, 2022:
2020 RPI
Royalty
Agreement
2021 RPI
Royalty
Agreement
OMERS
Royalty
Agreement
Total
Balance as of December 31, 2021$147,224 $153,377 $148,774 $449,375 
Deferred financing costs (34) (34)
Non-cash Interest expense on Royalty financing obligations10,165 6,327 3,157 19,649 
Royalty revenues paid and payable(4,385)(380) (4,765)
Balance as of March 31, 2022$153,004 $159,290 $151,931 $464,225 
Non-cash Interest expense on Royalty financing obligations10,462 6,020 3,224 19,706 
Royalty revenues paid and payable(5,764)(501) (6,265)
Balance as of June 30, 2022$157,702 $164,809 $155,155 $477,666 
Effective interest rate25.5 %12.1 %8.5 %
Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $8,531 as of June 30, 2022. The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.
Concurrent with entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the “Common Stock Purchase Agreement”), pursuant to which the Company sold common stock to RPI for a premium of $4,269. This premium has been deferred and is being amortized through interest expense using the effective interest method over the term of the applicable arrangement. Refer to Note 9 for further details on the common stock sale premium.
Note 7 Debt
Credit Agreement
On December 7, 2020, the Company entered into a $200,000 Credit Agreement (the “Credit Agreement”) with Athyrium Opportunities III Co-Invest 1 LP (“Athyrium”), as lender and as administrative agent for the lenders. Certain of the Company's direct and indirect subsidiaries are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the “Term A Loan”), which was received by the Company on December 7, 2020 and is recorded in “Secured term loan” on the Company’s balance sheet as of June 30, 2022. The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its prior credit facility with MidCap Financial Trust.
The Credit Agreement also provides for two additional term loans, at the Company’s option, in the respective principal amounts of $25,000 (the “Term B Loan”) and $50,000 (the “Term C Loan” and, collectively with the Term A Loan and the Term B Loan, the “Term Loans”). Both the Term B Loan and the Term C Loan were funded on July 29, 2022 in the aggregate principal amount of $75,000. Refer to Note 12 for further details on the funding of the Term B Loan and the Term C Loan. The maturity date of the Credit Agreement is December 7, 2025.
On November 19, 2021, the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the 2021 RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company did not draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (x) terminated the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to
19

draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.
The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date. For each of the first eight full fiscal quarters following December 7, 2020, the Company has the option to make the applicable interest payment in-kind (a “PIK Interest Payment”) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the three-month LIBOR rate, which shall be no less than 1.75% and no more than 3.50% (“LIBOR”), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%.
The three-month LIBOR was 2.3125% as of June 28, 2022, the LIBOR measurement date for the three-month interest period beginning July 1, 2022. Accordingly, this LIBOR rate plus 10.25% will be used to record interest expense for the three-month interest period beginning July 1, 2022.
Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company may make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the second anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (1) 102.00% of the principal amount of the Term Loan being prepaid plus (2) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the second anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the second and third anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the third and fourth anniversaries of the applicable Term Loan borrowing date, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the fourth anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.
The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company’s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. Additionally, as of the last day of each fiscal quarter (a “Test Date”), beginning with the first Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company may not permit consolidated net revenues from ORLADEYO sales in the United States for the four-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the “Revenue Tests”). If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a one-time right (the “Cure Right”) to repay in full the entire amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time. In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has not been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.
A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.
20

The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.
As of June 30, 2022, the Company had borrowings of $125,000 under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the six months ended June 30, 2022 and 2021 totaled $8,774 and $7,745, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing. As of June 30, 2022, borrowings, including the PIK Interest Payments, totaled $150,839. The principal balance of the borrowing, including PIK amounts, are accruing interest at a rate of 12.17%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level 2 in the fair value hierarchy.
As of June 30, 2022, deferred debt fees and issuance costs totaled $8,822 and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(339) and $(211), was recognized for the six months ended June 30, 2022 and 2021, respectively.
The Credit Agreement contains two provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does not believe either provision is probable.
Note 8 Lease Obligations
The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of June 30, 2022. Renewal options for the Company's leases range from 1 to 5 years in length and begin from 2023 through 2026.
Aggregate lease expense under operating leases was as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Aggregate lease expense$626 $461 $1,220 $913 

Other supplemental information related to leases was as follows:
As of June 30, 2022As of December 31, 2021
Weighted average remaining lease term8.5 years9.2 years
Weighted average discount rate10.9%11.2%
All of the Company’s leases qualify as operating leases. The following table summarizes the presentation in the consolidated balance sheets of the Company’s operating leases:
Balance Sheet LocationAs of June 30, 2022As of December 31, 2021
Assets:
Operating lease assets, netOther Assets$6,983 $6,472 
Liabilities:
Current operating lease liabilitiesLease financing obligation – current liabilities$2,134 $1,819 
Non-current operating lease liabilitiesLease financing obligation – long-term liabilities6,198 5,962 
Total operating lease liabilities$8,332 $7,781 
Operating lease assets are recorded net of accumulated amortization of $3,440 and $2,626 as of June 30, 2022 and December 31, 2021, respectively.
21

Cash paid for amounts included in the measurement of lease liabilities was $607 and $1,181 for the three and six months ended June 30, 2022, respectively, and $379 and $819 for the three and six months ended June 30, 2021, respectively.
Maturities of operating lease liabilities as of June 30, 2022, are as follows (in thousands):
2022 (remaining)$1,265 
20232,266 
20241,717 
20251,373 
2026617 
Thereafter6,734 
Total lease payments13,972 
Less imputed interest(5,640)
Total$8,332 
Note 9 Stockholders Equity
Sales of Common Stock
On April 24, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective on May 14, 2020 and allows the Company to sell up to $500,000 in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.
On March 1, 2021, the Company filed an automatic shelf registration statement on Form S-3 with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.
On November 19, 2021, concurrent with the Company entering into the 2021 RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued 3,846,154 shares of the Company’s common stock to RPI for an aggregate purchase price of $50,000, at a price of $13.00 per share, calculated based on the 20-day volume weighted average price. The $13.00 per share price represents a premium of $1.11 over the closing price of $11.89 of the Company’s common stock on November 17, 2021, the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $4,269 paid by RPI on the purchase of the Company’s common stock has been deferred and is being amortized as a component of interest expense of the 2021 RPI royalty financing obligation.
Note 10 Stock-Based Compensation
As of June 30, 2022, the Company had three stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (“Incentive Plan”), the Amended and Restated Inducemen